Hans-Georg Kopp

Head of Department

Robert Bosch Center for Tumor Diseases

Germany

Research Interests

Explore related searches

Professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Hans-Georg Kopp is the Head of Department at the Robert Bosch Center for Tumor Diseases in Germany. His research areas include survivorship programs for cancer patients, mechanisms of apoptosis, and the effects of targeted therapies in non-small cell lung cancer. He has published extensively on topics such as drug-tolerant cancer cells, personalized treatment approaches, and novel immunotherapy strategies. His recent work explores the clinical implications of new treatment regimens for advanced malignancies.

Articles (10)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (5)

Hubert Löwenheim

Professor and Chair

University of Tübingen

GERMANY

View details

Nikolaj Frost

Charité Universitätsmedizin Berlin - Campus Virchow-Klinikum

GERMANY

View details

Delvys Rodriguez-Abreu

Universidad de Las Palmas de Gran Canaria

SPAIN

View details

Bettina Weigelin

W2 Professor

University of Tübingen

GERMANY

View details

Bernhard Gillissen

Charité - Universitätsmedizin Berlin

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Hans-Georg Kopp

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.

Survivorship program including long-term toxicities and quality-of-life development over 10 years in a randomized trial in operable stage III non-small-cell lung cancer (ESPATUE).

BCL-2 and BOK regulate apoptosis by interaction of their C-terminal transmembrane domains.

ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC.

Germline findings in patients with advanced malignancies screened with paired blood–tumour testing for personalised treatment approaches

The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA.

Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer

Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407.

Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas.

Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial.

Collaborators (5)

Hubert Löwenheim

Nikolaj Frost

Delvys Rodriguez-Abreu

Bettina Weigelin

Bernhard Gillissen

Make your next move.